T
Thomas Powles
Researcher at Queen Mary University of London
Publications - 804
Citations - 57482
Thomas Powles is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 82, co-authored 655 publications receiving 39271 citations. Previous affiliations of Thomas Powles include Charing Cross Hospital & University of London.
Papers
More filters
WethankBarniandPetrelli 1 andSunetal 2 fortheirinterestin our report of the PISCES (Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer) trial. 3 We certainly agree with our colleagues that efficacy is the
Bernard Escudier,C. Porta,Thomas Powles,Tim Eisen,Cora N. Sternberg,Faisal Mehmud,David Cella +6 more
Journal ArticleDOI
101 presurgical sunitinib in metastatic clear cell renal cancer (mrcc): surgical safety and effect on the primary tumour
Thomas Powles,J. Peters,S. Horenblas,Wim Meinhardt,Timothy O'Brien,Anju Sahdev,Louise Lim,James Green,S. Chowdhury,V. Nargund,J. Bycroft,J. Hannen,Axel Bex +12 more
Journal ArticleDOI
Beyond Chemotherapy and Checkpoint Inhibitors: Weighing the Risks and Benefits of the Novel Therapies for Metastatic Urothelial Carcinoma
Journal ArticleDOI
Impact of the first surge of the COVID-19 pandemic on a tertiary referral centre for kidney cancer.
Teele Kuusk,Teele Kuusk,David Cullen,Joana B. Neves,Nicholas Campain,Ravi Barod,Ekaterini Boleti,Soha El-Sheihk,Lee Alexander Grant,John D. Kelly,Marta Marchetti,Faiz Mumtaz,Prasad Patki,Navin Ramachandran,Pedro Silva,My-Anh Tran-Dang,Miles Walkden,Maxine G. B. Tran,Thomas Powles,Axel Bex +19 more
TL;DR: In this paper, the impact of the COVID-19 pandemic on a centralized specialist kidney cancer care pathway was analyzed, and the authors conducted a retrospective analysis of patient and pathway characteristics including prioritization strategies at the Specialist Centre for Kidney Cancer located at the Royal Free London NHS Foundation Trust (RFH).
Journal ArticleDOI
Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survival.
Camilla Marisa Grunewald,Alina Henn,Matthew D. Galsky,Elizabeth R. Plimack,Lauren C. Harshman,Evan Y. Yu,Simon J. Crabb,Sumanta K. Pal,Ajjai Alva,Thomas Powles,Ugo De Giorgi,Neeraj Agarwal,Aristotelis Bamias,Sylvain Ladoire,Andrea Necchi,Ulka N. Vaishampayan,Cora N. Sternberg,Joaquim Bellmunt,Jack Baniel,Guenter Niegisch +19 more
TL;DR: In a large multi-institutional experience, 87% of patients who received adjuvant chemotherapy received it within the guideline recommended window of 90 days, while it was not possible to determine whether this is the optimal cut-off, early start of adjUvant chemotherapy seems to be reasonable.